Serum levels of Matrix Metalloproteinases (MMPs) in patients undergoing endovascular intervention for peripheral arterial disease.
暂无分享,去创建一个
[1] Jun Fan,et al. Distribution and Dynamic Changes in Matrix Metalloproteinase (MMP)-2, MMP-9, and Collagen in an In Stent Restenosis Process. , 2021, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[2] R. Serra,et al. Different inflammatory cytokines release after open and endovascular reconstructions influences wound healing , 2019, International wound journal.
[3] R. Serra,et al. Inflammatory biomarkers, vascular procedures of lower limbs, and wound healing , 2019, International wound journal.
[4] Hilary Graham,et al. The genesis and evolution of bead-based multiplexing. , 2019, Methods.
[5] J. Lantos,et al. Comparison of the perioperative time courses of matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) during carotid artery stenting (CAS) and carotid endarterectomy (CEA) , 2018, BMC Neurology.
[6] G. Santulli,et al. Update on peripheral artery disease: Epidemiology and evidence-based facts. , 2018, Atherosclerosis.
[7] Jeroen J. Bax,et al. Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). , 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[8] Jason L Johnson,et al. Metalloproteinases in atherosclerosis , 2017, European journal of pharmacology.
[9] I. Sagi,et al. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects. , 2017, Biochimica et biophysica acta. Molecular cell research.
[10] A. Spathis,et al. The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower Limb Endovascular Interventions for Peripheral Arterial Disease. , 2017, Annals of vascular surgery.
[11] S. George,et al. Evidence for the Involvement of Matrix-Degrading Metalloproteinases (MMPs) in Atherosclerosis. , 2017, Progress in molecular biology and translational science.
[12] S. Spiliopoulos,et al. Comparative Effectiveness of Plain Balloon Angioplasty, Bare Metal Stents, Drug-Coated Balloons, and Drug-Eluting Stents for the Treatment of Infrapopliteal Artery Disease , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[13] S. Gangemi,et al. Matrix metalloproteinases and risk stratification in patients undergoing surgical revascularisation for critical limb ischaemia , 2016, International wound journal.
[14] N. Papo,et al. Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine , 2016 .
[15] Jeffrey A. Jones,et al. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability , 2016, Journal of Vascular Research.
[16] S. Tyagi,et al. Regulation and involvement of matrix metalloproteinases in vascular diseases. , 2016, Frontiers in bioscience.
[17] N. Kucher,et al. Biological variation of established and novel biomarkers for atherosclerosis: Results from a prospective, parallel-group cohort study. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[18] Jun-peng Liu,et al. Matrix metalloproteinase 9 level as an indicator for restenosis following cervical and intracranial angioplasty and stenting , 2015, Neural regeneration research.
[19] M Hassan Murad,et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. , 2015, Journal of vascular surgery.
[20] S. Tyagi,et al. Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms , 2015, Vascular health and risk management.
[21] Ya Li. Correlation analysis of levels of adiponectin and matrix metalloproteinase-9 with stability of coronary heart disease. , 2015, Technology and Health Care.
[22] R. Vandenbroucke,et al. Is there new hope for therapeutic matrix metalloproteinase inhibition? , 2014, Nature Reviews Drug Discovery.
[23] K. Santos,et al. Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability , 2014, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[24] A. AbuRahma,et al. C-reactive protein and brain natriuretic peptide as predictors of adverse events after lower extremity endovascular revascularization. , 2013, Journal of vascular surgery.
[25] M. Libra,et al. Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. , 2012, Cytokine.
[26] M. Leinonen,et al. Elevated MMP‐8 and Decreased Myeloperoxidase Concentrations Associate Significantly with the Risk for Peripheral Atherosclerosis Disease and Abdominal Aortic Aneurysm 1 , 2010, Scandinavian journal of immunology.
[27] E. Boerwinkle,et al. Association of Circulating Matrix Metalloproteinases With Carotid Artery Characteristics: The Atherosclerosis Risk in Communities Carotid MRI Study , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[28] Jason L Johnson,et al. MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis , 2010, Cardiovascular research.
[29] M. Serio,et al. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. , 2008, International journal of cardiology.
[30] Jason L. Johnson,et al. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability , 2007, Expert review of cardiovascular therapy.
[31] John V. White,et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[32] Gillian Murphy,et al. Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.
[33] J. Sluijter,et al. Vascular Remodeling and Protease Inhibition—bench to Bedside , 2022 .
[34] Giuseppe Pennisi,et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease , 2005, Vascular medicine.
[35] G. Lip,et al. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity , 2005, Journal of internal medicine.
[36] T. Ludwig,et al. Microtubule-Dependent Matrix Metalloproteinase-2/Matrix Metalloproteinase-9 Exocytosis , 2004, Cancer Research.
[37] J. Álvarez-Sabín,et al. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. , 2004, Journal of vascular surgery.
[38] J. Plutzky. The vascular biology of atherosclerosis. , 2003, The American journal of medicine.
[39] R. Visse,et al. This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .
[40] U. Ikeda,et al. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. , 2002, Atherosclerosis.
[41] G. Cherr,et al. Metalloproteinase Inhibition and the Response to Angioplasty and Stenting in Atherosclerotic Primates , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[42] G. Pasterkamp,et al. Oral Matrix Metalloproteinase Inhibition and Arterial Remodeling After Balloon Dilation: An Intravascular Ultrasound Study in the Pig , 2001, Circulation.
[43] G Pasterkamp,et al. Arterial Remodeling: Mechanisms and Clinical Implications , 2000 .
[44] J. Verheijen,et al. Angioplasty : A Study in the Atherosclerotic Yucatan Micropig Metalloproteinase Inhibition Reduces Constrictive Arterial Remodeling After Balloon , 2000 .
[45] J. Woessner,et al. Matrix Metalloproteinases* , 1999, The Journal of Biological Chemistry.
[46] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.